Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustained cell culture.
GRAFF S, McCARTY KS. GRAFF S, et al. Exp Cell Res. 1957 Oct;13(2):348-57. doi: 10.1016/0014-4827(57)90014-9. Exp Cell Res. 1957. PMID: 13480302 No abstract available.
Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents.
Gobbo M, Joy J, Guedes H, Shazib MA, Anderson C, Abdalla-Aslan R, Peechatanan K, Lajolo C, Nasir KS, Gueiros LA, Nagarajan N, Hafezi Motlagh K, Kandwal A, Rupe C, Xu Y, Ehrenpreis ED, Tonkaboni A, Epstein JB, Bossi P, Wardill HR, Graff SL. Gobbo M, et al. Among authors: graff sl. Expert Opin Pharmacother. 2024 May 29:1-16. doi: 10.1080/14656566.2024.2354451. Online ahead of print. Expert Opin Pharmacother. 2024. PMID: 38808634 Review.
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.
Freedman RA, Caswell-Jin JL, Hassett M, Somerfield MR, Giordano SH; Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer Guideline Expert Panel. Freedman RA, et al. J Clin Oncol. 2024 May 20:JCO2400886. doi: 10.1200/JCO.24.00886. Online ahead of print. J Clin Oncol. 2024. PMID: 38768407
Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).
Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, Jacene H, Rubio IT, Schoones JW, Peeters MV, Poortmans P, Mann RM, Graff SL, Dibble EH, de Geus-Oei LF. Vaz SC, et al. Among authors: graff sl. Eur J Nucl Med Mol Imaging. 2024 May 14. doi: 10.1007/s00259-024-06696-9. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38740576
Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.
Heiss JD, Ray-Chaudhury A, Kleiner DE, Ehrlich DJ, Scott G, Edwards NA, Goldstein DS, Hammoud DA, Hadaczek P, Van Laar VS, Graff SA, Herscovitch P, Lungu C, Hallett M, Lonser RR, Zaghloul KA, Bankiewicz KS. Heiss JD, et al. Among authors: graff sa. Mov Disord. 2024 May 8. doi: 10.1002/mds.29820. Online ahead of print. Mov Disord. 2024. PMID: 38718138
Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines.
Groheux D, Vaz SC, Ulaner GA, Cook GJR, Woll JPP, Mann RM, Poortmans P, Cardoso F, Jacene H, Graff SL, Rubio IT, Peeters MV, Dibble EH, de Geus-Oei LF. Groheux D, et al. Among authors: graff sl. Eur J Nucl Med Mol Imaging. 2024 May 2. doi: 10.1007/s00259-024-06694-x. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38693453 No abstract available.
The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors.
Kareff SA, Trabolsi A, Krause HB, Samec T, Elliott A, Rodriguez E, Olazagasti C, Watson DC, Bustos MA, Hoon DSB, Graff SL, Antonarakis ES, Goel S, Sledge G, Lopes G. Kareff SA, et al. Among authors: graff sl. Cancers (Basel). 2024 Apr 19;16(8):1572. doi: 10.3390/cancers16081572. Cancers (Basel). 2024. PMID: 38672653 Free PMC article.
212 results